Cargando…
Targeting cholesterol homeostasis in lung diseases
Macrophages are critical to organ structure and function in health and disease. To determine mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling normally maintains surfactant homeostasis and how its disruption causes pulmonary alveolar proteinosis (PAP), we evalua...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579240/ https://www.ncbi.nlm.nih.gov/pubmed/28860566 http://dx.doi.org/10.1038/s41598-017-10879-w |
_version_ | 1783260669118775296 |
---|---|
author | Sallese, Anthony Suzuki, Takuji McCarthy, Cormac Bridges, James Filuta, Alyssa Arumugam, Paritha Shima, Kenjiro Ma, Yan Wessendarp, Matthew Black, Diane Chalk, Claudia Carey, Brenna Trapnell, Bruce C. |
author_facet | Sallese, Anthony Suzuki, Takuji McCarthy, Cormac Bridges, James Filuta, Alyssa Arumugam, Paritha Shima, Kenjiro Ma, Yan Wessendarp, Matthew Black, Diane Chalk, Claudia Carey, Brenna Trapnell, Bruce C. |
author_sort | Sallese, Anthony |
collection | PubMed |
description | Macrophages are critical to organ structure and function in health and disease. To determine mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling normally maintains surfactant homeostasis and how its disruption causes pulmonary alveolar proteinosis (PAP), we evaluated lipid composition in alveolar macrophages and lung surfactant, macrophage-mediated surfactant clearance kinetics/dynamics, and cholesterol-targeted pharmacotherapy of PAP in vitro and in vivo. Without GM-CSF signaling, surfactant-exposed macrophages massively accumulated cholesterol ester-rich lipid-droplets and surfactant had an increased proportion of cholesterol. GM-CSF regulated cholesterol clearance in macrophages in constitutive, dose-dependent, and reversible fashion but did not affect phospholipid clearance. PPARγ-agonist therapy increased cholesterol clearance in macrophages and reduced disease severity in PAP mice. Results demonstrate that GM-CSF is required for cholesterol clearance in macrophages, identify reduced cholesterol clearance as the primary macrophage defect driving PAP pathogenesis, and support the feasibility of translating pioglitazone as a novel pharmacotherapy of PAP. |
format | Online Article Text |
id | pubmed-5579240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-55792402017-09-06 Targeting cholesterol homeostasis in lung diseases Sallese, Anthony Suzuki, Takuji McCarthy, Cormac Bridges, James Filuta, Alyssa Arumugam, Paritha Shima, Kenjiro Ma, Yan Wessendarp, Matthew Black, Diane Chalk, Claudia Carey, Brenna Trapnell, Bruce C. Sci Rep Article Macrophages are critical to organ structure and function in health and disease. To determine mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling normally maintains surfactant homeostasis and how its disruption causes pulmonary alveolar proteinosis (PAP), we evaluated lipid composition in alveolar macrophages and lung surfactant, macrophage-mediated surfactant clearance kinetics/dynamics, and cholesterol-targeted pharmacotherapy of PAP in vitro and in vivo. Without GM-CSF signaling, surfactant-exposed macrophages massively accumulated cholesterol ester-rich lipid-droplets and surfactant had an increased proportion of cholesterol. GM-CSF regulated cholesterol clearance in macrophages in constitutive, dose-dependent, and reversible fashion but did not affect phospholipid clearance. PPARγ-agonist therapy increased cholesterol clearance in macrophages and reduced disease severity in PAP mice. Results demonstrate that GM-CSF is required for cholesterol clearance in macrophages, identify reduced cholesterol clearance as the primary macrophage defect driving PAP pathogenesis, and support the feasibility of translating pioglitazone as a novel pharmacotherapy of PAP. Nature Publishing Group UK 2017-08-31 /pmc/articles/PMC5579240/ /pubmed/28860566 http://dx.doi.org/10.1038/s41598-017-10879-w Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Sallese, Anthony Suzuki, Takuji McCarthy, Cormac Bridges, James Filuta, Alyssa Arumugam, Paritha Shima, Kenjiro Ma, Yan Wessendarp, Matthew Black, Diane Chalk, Claudia Carey, Brenna Trapnell, Bruce C. Targeting cholesterol homeostasis in lung diseases |
title | Targeting cholesterol homeostasis in lung diseases |
title_full | Targeting cholesterol homeostasis in lung diseases |
title_fullStr | Targeting cholesterol homeostasis in lung diseases |
title_full_unstemmed | Targeting cholesterol homeostasis in lung diseases |
title_short | Targeting cholesterol homeostasis in lung diseases |
title_sort | targeting cholesterol homeostasis in lung diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579240/ https://www.ncbi.nlm.nih.gov/pubmed/28860566 http://dx.doi.org/10.1038/s41598-017-10879-w |
work_keys_str_mv | AT salleseanthony targetingcholesterolhomeostasisinlungdiseases AT suzukitakuji targetingcholesterolhomeostasisinlungdiseases AT mccarthycormac targetingcholesterolhomeostasisinlungdiseases AT bridgesjames targetingcholesterolhomeostasisinlungdiseases AT filutaalyssa targetingcholesterolhomeostasisinlungdiseases AT arumugamparitha targetingcholesterolhomeostasisinlungdiseases AT shimakenjiro targetingcholesterolhomeostasisinlungdiseases AT mayan targetingcholesterolhomeostasisinlungdiseases AT wessendarpmatthew targetingcholesterolhomeostasisinlungdiseases AT blackdiane targetingcholesterolhomeostasisinlungdiseases AT chalkclaudia targetingcholesterolhomeostasisinlungdiseases AT careybrenna targetingcholesterolhomeostasisinlungdiseases AT trapnellbrucec targetingcholesterolhomeostasisinlungdiseases |